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NKG2D is a potent activating receptor on natural
killer (NK) cells and acts as a molecular sensor for
stressed cells expressing NKG2D ligands such as in-
fected or tumor-transformed cells. Although NKG2D
is expressed on NK cell precursors, its role in NK cell
development is not known. We have generated
NKG2D-deficient mice by targeting the Klrk1 locus.
Herewe provide evidence for an important regulatory
role of NKG2D in the development of NK cells. The
absence of NKG2Dcaused faster division of NK cells,
perturbation in size of some NK cell subpopulations,
and their augmented sensitivity to apoptosis. As
expected, Klrk1/ NK cells are less responsive to
tumor targets expressing NKG2D ligands. Klrk1/
mice, however, showed an enhanced NK cell-medi-
ated resistance to mouse cytomegalovirus infection
as a consequence of NK cell dysregulation. Alto-
gether, these findings provide evidence for regula-
tory function of NKG2D in NK cell physiology.
INTRODUCTION
NKG2D is an activating receptor expressed on all mature natural
killer (NK) cells and on NK precursors (NKPs) (Huntington et al.,
2007b). NKG2D is also present on NKT cells, some gd T cells,
andactivatedormemoryabTcells (Raulet, 2003;Saez-Borderias
et al., 2006). Unlike other NKG2 molecules, NKG2D is a homo-
dimer that recognizesmainly stress-inducedmajor histocompat-
ibility complex (MHC) class I-like ligands such as Rae-1 family
(a, b, g, d, and 3), H60, andMULT-1 inmice, as well asMHC class
I chain-related molecules (MICA or MICB) and UL16-binding
proteins (ULBP1-4 or RAET1G) in humans (Bacon et al., 2004;
Raulet, 2003). Thus, NKG2D receptor acts as a molecular sensor
for stress-affected cells and can even override the inhibitory
receptorsengagedbyMHCclass I orMHC-class-I-likemolecules.
NKG2D homodimer associates with two adaptor proteins with
signaling properties, DAP10 and DAP12, which possess p85
phosphatidylinositol 3-kinase (PI3K)-binding YINM motif and270 Immunity 31, 270–282, August 21, 2009 ª2009 Elsevier Inc.immunotyrosine-based activation motif (ITAM), respectively
(Gilfillan et al., 2002;Wu et al., 2000;Wu et al., 1999). DAP10 acti-
vates PI3K, which is mainly responsible for cytotoxicity and
survival of NK cells, as well as for costimulation of T cells,
whereas DAP12 activates Src family kinases (ZAP70 and Syk),
which are required for cytokine release and enhancement of
cytotoxicity of NK cells. As a consequence of alternative
NKG2D RNA splicing, there are two NKG2D isoforms, with
shorter (NKG2D-S) and longer (NKG2D-L) intracellular domains.
NKG2D-S is capable of binding both adaptor proteins, whereas
NKG2D-L binds only DAP10 (Diefenbach et al., 2002; Gilfillan
et al., 2002). Both isoforms are expressed in mouse, whereas
only NKG2D-L exists in human NK cells.
The role of NKG2D in effector functions of the innate and adap-
tive immunity has been extensively studied in different experi-
mental models. Various tumor cell lines expressing NKG2D
ligands can activate NK or CD8+ T cells and induce their cytotox-
icity in an NKG2D-dependent manner in vitro as well as in vivo
(Bauer et al., 1999; Cerwenka et al., 2001; Diefenbach et al.,
2001; Groh et al., 2001). NKG2D also senses cells expressing
NKG2D ligands induced by the DNA-damage response pathway
(Gasser et al., 2005). Thus, it is implicated in the control of tumor
transformation as well as spontaneous tumor growth in vivo
(Bartkova et al., 2005; Gorgoulis et al., 2005; Guerra et al., 2008).
The role of NKG2D was also shown in graft rejection (Ogasa-
wara et al., 2005), autoimmunity (Ogasawara et al., 2004), and
the control of virus infections and other intracellular pathogens
(Cosman et al., 2001; Groh et al., 2001; Jonjic et al., 2008;
Wiemann et al., 2005). To overcome NK cell activation via
NKG2D, bothmouse (MCMV) and human (HCMV) cytomegalovi-
ruses encode proteins and/or microRNA aimed at downmodula-
tion of the expression of cellular NKG2D ligands (Jonjic et al.,
2008). Thus, MCMV appears to specifically target the NKG2D
receptor, suggesting that NKG2D-mediated control is critical
to modulating MCMV infections.
Any role for NKG2D in control of MCMV infections in C57BL/6
mice needs to account for the dominant role of Klra8 (encoding
Ly49H) in genetic resistance to MCMV. Ly49H couples to the
ITAM-containing DAP12 signaling chain and is an activation
receptor expressed only on NK cells (Lanier and Bakker, 2000).
Consistent with this expression, depletion of NK cells confers
enhanced susceptibility to MCMV. Moreover, in the absence of
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DAP12, otherwise resistant C57BL/6 mice cannot control early
MCMV infection (Brown et al., 2001; Daniels et al., 2001; Lee
et al., 2001; Sjolin et al., 2002). Ly49H recognizes the MHC-class-
I-like molecule, m157, that is encoded by MCMV (Arase et al.,
2002; Smith et al., 2002). In the absence of m157 gene, Ly49H-
dependent control is not seen in most tissues (Bubic et al., 2004).
Taken together, these data suggest that NKG2D works in concert
with Ly49H to mediate NK cell resistance to MCMV, but it has not
yet been possible to study the effects of NKG2D because of the
multiple MCMV open reading frames (ORFs) that target NKG2D.
To investigate NKG2D functions in vivo for various immune cells
expressing this receptor, we have developed a NKG2D-deficient
mouse strain by targeting the Klrk1 genetic locus (encoding
NKG2D). Here we provide evidence that NKG2D plays an impor-
tant regulatory role in the development, homeostasis, and survival
of NK cells. NK cells in Klrk1/ mice proliferated faster, showed
differential expression of several developmental markers, and
exhibited augmented susceptibility to apoptosis, as compared to
control mice. Klrk1/ NK cells were markedly less responsive to
NKG2D-sensitive tumor targets, but they retained their reactivity
when triggered byother activating receptors or cytokines.Klrk1/
Figure 1. Generation of NKG2D-Deficient
Mice
(A) Targeting of the Klrk1 locus. Partial restriction
map of the Klrk1 locus with restriction sites for
EcoR I (E) and Stu I (S) is shown. Selectionmarkers
(HSV-tk and neo), loxP sites (<), external hybrid-
ization probes a and b, and internal probe c are de-
picted. The expected sizes of the DNA fragments
are indicated above the lines.
(B andC)Southern-blot analyses of the targetedES
clones. (B) The homologous recombination as well
as the introducedmutation in the second exonwas
tested by EcoR I digestion and external probe a.
The DNA fragments of 3.7 and 6 kb represent tar-
geted and WT NKG2D allele, respectively. (C) The
Cre-mediated deletion of the neo cassette (Dneo)
in the targeted ES clones (neo) was tested by the
Stu I digestion and the external probe b. The DNA
fragments of 12.8, 6.9, and 14 kb representing
Dneo, neo, andWTalleles, respectively, are shown.
(D) Flow-cytometric analysis of NKG2D expression
on the spleen CD33CD19NK1.1+ NK cells of
C57BL/6 (dotted line), Klrk1+/ (dashed line), and
Klrk1/ (line) is shown.
mice showed enhanced resistance to
MCMV infection as a consequence of the
observed NK cell dysregulation. During
the infection, Klrk1/ NK cells mature
faster, and a larger fraction of them are
capable to exert their effector functions.
RESULTS
Targeting of the Klrk1 Locus
and Generation of Klrk1/ Mice
Targeting of the Klrk1 locus was per-
formed with the targeting vector contain-
ing the first six exons of the Klrk1 gene and embryonic stem (ES)
cells derived from C57BL/6 mice. In order to completely inacti-
vate both NKG2D-L and NKG2D-S receptor variants, we
mutated their leading ATGs in the coding sequence by intro-
ducing an EcoR I site in the second exon and an EGFP coding
sequence with a transcriptional stop signal (SV40pA) followed
by loxP-flanked neomycin resistance cassette (neo) in the third
exon. The wild-type Klrk1 locus and the locus upon homologous
recombination of the targeting vector are depicted in Figure 1A.
Cre-mediated deletion of the neo in the recombinant ES cells
created the desired Klrk1 allele (Figure 1A). Homologous
recombinants were identified by Southern blotting (Figure 1B)
and checked for random integration of the vector (data not
shown) and for the deletion of the neo cassette upon transient
Cre expression (Figure 1C). The mutated NKG2D allele was
subsequently transmitted into the mouse germline, which was
confirmed by polymerase chain reaction (PCR) and Southern
blotting (data not shown).
The Klrk1/mice bred normally and gave offspring according
to the expected Mendelian ratio. Expression of NKG2D on NK
cells isolated from the spleen of Klrk1/ mice was completely
abolished (Figure 1D). In Klrk1+/ mice, however, NKG2D wasImmunity 31, 270–282, August 21, 2009 ª2009 Elsevier Inc. 271
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NKG2D Regulates NK Cell Development and SurvivalFigure 2. Reduced Cell Numbers in the Spleen of Klrk1/ Mice
(A) Cell numbers in the spleen and inguinal lymph nodes from 810-week-old C57BL/6, Klrk1+/, or Klrk1/ mice are shown.
(B) Percentages and absolute numbers of NK (CD3CD19NK1.1+) and B cells (CD19+) isolated from the spleen and inguinal lymph nodes of C57BL/6 and
Klrk1/ mice are shown. Each symbol represents an individual mouse. Horizontal lines represent mean values. Statistically significant differences between
the groups are indicated by asterix symbols.reduced in comparison to the C57BL/6 control. The expression
of NKG2D ligands as well asMHC Imolecules onmouse-derived
embryonic fibroblasts (MEFs) was comparable betweenKlrk1/
and C57BL/6 mice, as confirmed by specific mAb and NKG2D
tetramer staining (data not shown). Unfortunately, we have not
observed any of the expected expression of EGFP in NK cells
carrying the knock-in allele. By sequence analysis of the target-
ing vector, we subsequently found that the Kozak sequence at
the leading ATG of the EGFP coding sequence was deleted
during the subcloning procedure.
Reduced Number of Cells in the Spleen of Klrk1/Mice
First we analyzed lymphocyte populations in the spleen and
inguinal lymph nodes of the mutant and control mice to see
whether the absence of NKG2D causes any abnormalities. We
noticed that the spleen of adult Klrk1/ mice contained lower
numbers of cells in comparison to the age-matched C57BL/6
control mice (Figure 2A). The observed cell loss was mainly272 Immunity 31, 270–282, August 21, 2009 ª2009 Elsevier Inc.due to the reduced numbers of B and T cells (Figure 2B, Fig-
ure S1A available online) because population sizes of NK and
NKT cells were comparable to the control (Figure 2B, Fig-
ure S1A). In contrast to the spleen, the numbers of total cells
as well as of all lymphocyte populations (T, B, NK, and NKT) in
inguinal lymph nodes were comparable to the control (Figure 2A,
Figure S1A). Considering the reduced number of cells in the
spleen, we also analyzed T and B cell development in Klrk1/
mice. We found no significant difference in total cell numbers
or in the typical T and B cell subpopulations of the thymus and
bone marrow, respectively (Figures S1C and S1D). Together,
these results indicate that the reduction of T and B cells in the
spleen, but not in the lymph nodes of Klrk1/ mice, is due to
organ-specific differences in homeostasis.
NKG2D Plays a Role in NK Cell Development
Because NKG2D is expressed very early in the NK cell develop-
ment (Huntington et al., 2007b), next we sought to test whether
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cells. A set of markers characteristic for different developmental
stages was used for the analysis of CD33CD19NK1.1+ NK
cells from the bone marrow and spleen of 9-week-old Klrk1/
mice and their B6 littermates. A significant reduction of the NK
cell population expressing c-Kit (CD117) in the bone marrow
as well as in the spleen of Klrk1/ mice was observed (Fig-
ure 3A). In contrast, NK cell populations expressing CD127 and
CD51 were at comparable frequency and slightly increased,
respectively, in the bone marrow and present at reduced
frequency in the spleen (Figure 3A). A similar pattern was also
observed on 24-week-old littermates (Figure S2B).
We noticed that the reduction of c-Kit+ cells in the spleen (and
to a lesser extent in the bonemarrow) occurredmostly in the frac-
tion of CD127NK1.1+ (p < 0.001) or CD51NK1.1+ (p < 0.001)
NK cells (stages IV–V), whereas the fraction of CD127+NK1.1+
or CD51+NK1.1+ (stage III) c-Kit+ NK cells remained mostly unaf-
fected (Figure 3B). In contrast, we observed a low percentage
and no statistically significant difference in the c-Kit+ subpopula-
tion of CD122+NK1.1 NK cells (stage I) from the bone marrow
and spleen, indicating that the reduction of c-Kit+ NK cells
occurs in the transition from immature to mature NK cells rather
than earlier (Figure 3B).
Other molecules that begin to be expressed at the immature
stage (stages II–III), such as CD27, CD94, NKG2A, and most of
the Ly49 family receptors (C, D, G2, H, and I), were expressed
on NK cells in the bone marrow and spleen at amounts compa-
rable to the control (Figure 3C, data not shown, Figure S2A).
However, NK cells expressing Ly49A were significantly reduced
in the bonemarrow and the spleen (data not shown, Figure S2A).
We also noticed a decrease of CD11bhi and CD43hi as well as
Klrg1+ populations of NK cells in the bone marrow but not in
the spleen and liver, where they were at comparable sizes to
the control (Figure 3C; Figure S3D). No difference in the
frequency and absolute expression of activating (Ncr1, 2B4,
and CD16) and inhibitory (NKPR1D) receptors on NK cells was
observed (data not shown). In conclusion, the absence of
NKG2D influences NK cell development, which is indicated by
altered proportion of immature NK cells expressing c-Kit,
CD51, and Ly49A, as well as mature cells expressing CD11bhi,
CD43hi, and Klrg1+.
Faster Division of NK Cells in Klrk1/ Mice
Considering the observed alterations of NK cell development in
Klrk1/ mice, we sought to test the properties of Klrk1/ NK
cells that might affect their developmental phenotype. First, we
checked the proliferation dynamics of NK cells in vivo. Klrk1/
and control mice were pulsed with BrdU for 11 days and then
checked for the decay of BrdU+ NK cells in the bone marrow
and spleen at day 0, 15, and 21. Immediately after the pulse
(day 0), a higher percentage of NK cells in the bone marrow of
Klrk1/ mice (70.26% ± 4.11%) was labeled in comparison to
the control (60.52% ± 3.72%), indicating their faster proliferation
rate. This was not the case in the spleen (Figure 4A). However,
the decay of BrdU+ NK cells was significantly faster in both
bone marrow and spleen of Klrk1/ mice, indicating a different
proliferation and/or apoptosis rate of these cells between the
strains (Figure 4A). The calculated half-time of the decay in the
bone marrow of Klrk1/ mice (t1/2 = 10.84 days) was approxi-mately 50% shorter than in C57BL/6 mice (t1/2 = 23.11 days).
In the spleen of both strainswe observed longer decay half-times
than in the bone marrow but similar difference between them
(Figure 4A).
In order to see the contribution of different NK subsets to the
BrdU labeling and decay, we also analyzed NK cells regarding
the expression of c-Kit and CD11b. We looked at the expression
of c-Kit versus CD11b on gated CD3CD19NK1.1+BrdU+ NK
cells (Figure 4B) at day 0. Among the proliferating cells in the
bone marrow of NKG2D-deficient mice, we observed the
following: a larger population of c-Kit CD11blo (stage II), a
reduced population of c-Kit+CD11blo (stage III–IV), and compa-
rable populations of c-Kit+CD11bhi and c-KitCD11bhi NK cells
(stage V) to B6 control (Figure 4B). The differences observed in
the bone marrow were much more pronounced in the spleen.
There we found a robust increase of c-KitCD11blo NK cells
(stage II) as well as the reduction of the c-Kit+CD11blo (stage
III–IV) and c-Kit+CD11bhi (stage V) populations of NK cells. The
subpopulation of c-KitCD11bhi NK cells (stage V) was at
a comparable number with B6 control, as also seen in the
bone marrow. Together, these data suggest that the reduction
in the percentage of c-Kit+ NK cells in NKG2D-deficient mice is
a consequence of a higher proliferation rate of immature NK cells
(stage II) and/or faster differentiation and transition from the
stage III to the more mature stage V accompanied by downmo-
dulation of c-Kit.
Next we followed the BrdU decay dynamics of CD11blo
and CD11bhi NK cell subpopulations. The percentages of
CD11bloBrdU+ and CD11bhiBrdU+ out of total CD11blo and
CD11bhi NK cell subpopulations, respectively, were followed at
indicated time points (Figure S3A). In the bone marrow of
Klrk1/ mice, the decay half-time of less mature, CD11blo NK
cells (Figure S3A) was shorter than in the control mice and very
similar to the decay dynamics of total BrdU+ NK cells (Figure 4A).
More mature CD11bhi NK cells (Figure S3A) had similar decay
dynamics to CD11blo NK cells in Klrk1/ as well as in control
mice. Note that a higher percentage of CD11bhiKlrk1/NK cells
(63.7% ± 7.29%) was initially BrdU labeled (day 0) in comparison
to the control (48.26% ± 3.52%), indicating faster proliferation
and transition from the less mature to the more mature NK cell
compartment during the pulse period. The situation in the spleen
was quite similar for the CD11blo subpopulation of NK cells to
that described for the bone marrow (Figure S3A). Within the
fraction of CD11bhi NK cells (Figure S3A), we observed more
pronounced difference (over 3-fold) in the decay half-times
between the groups, which was mostly due to the slower decay
of these cells in control mice.
Because we observed faster decay of BrdU-labeled NK cells,
next we tested whether a differential susceptibility to apoptosis
may explain, at least partially, this finding. NK cells were cultured
either without treatment or with addition of rIL-15 (0.5 or 5 ng/ml)
or rIL-2 (1000 U/ml), and apoptotic cells were determined upon
14 hr of culture by Annexin V staining. As shown in Figure 4C,
higher susceptibility of Klrk1/NK cells to apoptosis in compar-
ison to the control was observed. IL-15 (Figure 4C) or IL-2 (data
not shown) prevented to some extent apoptosis in both types of
cells, but a significant difference between them in the suscepti-
bility to apoptosis remained. Thus, Klrk1/ NK cells are more
susceptible to apoptosis and at the same time more resistantImmunity 31, 270–282, August 21, 2009 ª2009 Elsevier Inc. 273
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Analysis of NK cell subsets in the bone marrow and spleen of 9-week-old Klrk1/ mice and their B6 litermates.
(A) Comparison of c-Kit+, CD127+, and CD51+ subpopulations of CD33CD19NK1.1+ NK cells in the bone marrow and spleen.
(B) The representative dot-plot analyses of c-Kit, CD127, and CD51expression on CD33CD19CD122+NK1.1+ NK cells are shown. Comparisons of c-Kit+
subpopulation of CD33CD19NK1.1 NK cells in the bone marrow and spleen are shown (bar plots).
(C) Analyses of CD27, CD11b, CD43, and Klrg1 expression on CD33CD19NK1.1+ NK cells are shown. Indicated numbers as well as bar plots (A, B, and C)
represent mean percentages ± standard deviation (SD) of individual data from four independent experiments (3–5 mice per group in each).274 Immunity 31, 270–282, August 21, 2009 ª2009 Elsevier Inc.
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NKG2D Regulates NK Cell Development and SurvivalFigure 4. Faster Division of NK Cells in Klrk1/ Mice
(A and B) C57BL/6 (B6) and Klrk1/mice were pulsed with BrdU in the drinking water for 11 days. (A) A decay of BrdU+ NK cells in the bonemarrow and spleen at
day 0, 15, and 21 is shown. Half-times (t1/2) of the decay as well as goodness-of-fit (r
2) of the linear regressions are indicated. Representative of three independent
experiments (3–4mice per group in each) is shown. (B) Analyses of c-Kit and CD11bmarkers on BrdU+ NK subsets after 11 days of the BrdU treatment (day 0) are
shown. Indicated numbers in dot plots represent mean percentages ± SD of individual data. The analysis shown here is representative of three independent
experiments (3–4 mice per group in each).
(C) Higher susceptibility of Klrk1/ NK cells to apoptosis. Freshly isolated cells from the spleen of C57BL/6 or Klrk1/mice were cultured either without or with
rIL-15 (0.5 or 5 ng/ml). Apoptotic cells were determined upon 14 hr of culture by Annexin V staining. Bars represent mean percentages ± SD of individual data. The
results shown here are representative of three independent experiments (3–5 mice per group in each).to the IL-15-mediated rescue in comparison to the NKG2D-suffi-
cient cells.
Klrk1/ NK Cells Are Less Responsive to Tumor
Targets Expressing NKG2D Ligands
Next we sought to see how Klrk1/ NK cells respond to several
tumor cell lines expressing NKG2D ligands. First we tested the
capacity of Klrk1/ NK cells to kill tumor cell targets. NK cyto-
toxic assay was performed with NKG2D-sensitive and -resistant
(RMA) tumor cells targets. As expected, Klrk1/ NK cells were
less able to kill NKG2D-sensitive targets such as RMA-Rae1d
or YAC1 than control Klrk1+/+ cells (Figure 5A). RMA cells were
resistant to both NK cells tested (Figure 5A). We obtained also
very similar results when we tested IFN-g response of NK cells
to the same tumor targets (Figure 5B). Thus, these resultsconfirmed that NKG2D signaling has an important role for the
effector functions of NK cells.
We also testedwhether Klrk1/NK cells are able to recognize
and kill MHC-class-I-deficient targets. RMA and RMA/S cells as
targets were used in the analysis. As depicted in Figure S3B,
Klrk1/ NK cells were equally efficient in the killing of MHC-
class-I-negative RMA/S cells as compared to the control NK
cells. Thus, NK cells in NKG2D-deficient mice are educated to
recognize and respond to ‘‘missing self.’’
Larger Fraction of Klrk1/ NK Cells Is Capable
of Producing IFN-g
Next we tested the ability of Klrk1/ NK cells to produce IFN-g
upon the activation with various stimuli. NK cells isolated from
the spleen of Klrk1/ and C57BL/6 mice were subjected toImmunity 31, 270–282, August 21, 2009 ª2009 Elsevier Inc. 275
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tors. Upon triggering of NK1.1, Ly49H, or Ly49D receptors,
a somewhat larger fraction of Klrk1/ NK cells produced IFN-g
as compared to control NK cells (Figure 5C). Although these
differences were variable in the series of experiments, the
tendency for somewhat larger responses by Klrk1/ NK cells
was consistently observed. We obtained similar results upon
Figure 5. Functional Properties of Klrk1/ NK Cells
(A) NK cytotoxic assay. Equilibrated NK cells from the spleen of Klrk1/ and
C57BL/6 mice were incubated with 104 CFSE-labeled target cells for 4 hr at
37C and in the presence of rIL-2 (1000 U/ml). Triplicates of samples for
each effector to target (E:T) ratio were analyzed by flow cytometry. Values
represent mean percentages ± SD of individual data. The results shown here
are representative of three independent experiments (3–4 mice per group in
each).
(B) NK cells from the spleen ofKlrk1/ andC57BL/6micewere incubated with
the tumor cell targets in 1:1 ratio for 7 hr. The IFN-g productionwas determined
by the intracellular staining. Dot-plot analysis shown here is representative of
three independent experiments (3 mice per group in each).
(C) NK cells were in vitro stimulated either by immobilized mAbs (aNK1.1,
aLy49H, or aLy49D) or by incubation with CHO cell line, rIL-12, or PMA and
Ionomycin. After an incubation period of 9 hr, intracellular IFN-g was deter-
mined. When NK cells were stimulated with aNK1.1, they were stained with
aDX5 mAb. Bars represent mean percentages ± SD of individual data. The
analysis is representative of four independent experiments (3 mice per group
in each).276 Immunity 31, 270–282, August 21, 2009 ª2009 Elsevier Inc.the incubation of NK cells with Chinese hamster ovary (CHO)
cell line (Figure 5C) expressing Ly49D ligands (Idris et al., 1999),
as well as after stimulation with IL-12 (Figure 5C). However, after
either type of stimulation, we did not observe a difference in the
quantity of IFN-g production per cell between the tested NK cells
(data not shown).
Enhanced NK Cell-Mediated Resistance to MCMV
Infection in the Klrk1/ Mice
In our next experiments we sought to analyze the capacity of
Klrk1/ NK cells to control MCMV infection in vivo. Because
our mutant mice were on the C57BL/6 background, the mutant
MCMV lacking m157 gene (Dm157) had to be used. Namely,
the resistance toMCMV of C57BL/6 is mainly due to themassive
activation of NK cells via Ly49H receptors, which recognize
MCMV m157 gene product (Arase et al., 2002; Smith et al.,
2002). Groups of Klrk1/, Klrk1+/, and C57BL/6 mice (8–10
weeks old) were treated with PBS, aNK1.1, or aNKG2D prior to
the intravenous infection. After 4 days, the mice were sacrificed
and virus titers were determined in the spleen, liver, and lungs.
Surprisingly, Klrk1/ mice were significantly better (liver and
spleen, Figure 6A) or equal (lungs, data not shown) in the control
of virus as compared to C57BL/6 mice. Similar results were
obtained in independent experiments using 9-week-old mouse
littermates as depicted in Figure S3C. In heterozygous mice,
the virus titers in the spleen and liver were between the titers
observed in the other two groups of mice, indicating that already
lower amount of NKG2D expression (Figure 1D) in these mice
positively influences the early immunosurveillance of the virus.
Depletion of NK cells completely abrogated the observed effect,
thus showing its NK cell dependency. As expected, neutraliza-
tion of NKG2D had no effect on the virus control in all tested
organs of Klrk1/ mice, whereas it had a slight or moderate
effect in C57BL/6 mice. The question is whether one can inter-
pret the inhibition of NKG2D by mAb (in C57BL/6 mice) in
a similar way as NKG2D deficiency. One assumes that the
injected antibody has the capacity to block NKG2D function to
the same degree in every tissue, but this may not be the case.
These differences may give rise to tissue-specific effects. On
the other hand, our results indicate that the difference between
the results obtained when comparing NKG2D-deficient mice
and blocking of NKG2D in B6 mice by mAbs is a reflection of
a higher responsiveness of NKG2D-deficient NK cells as a result
of altered NK cell development (see above).
Because the less virulent tissue-culture-grown virus was used
in the above experiment, next we tested the more virulent sali-
vary gland isolate of wild-type MCMV (SGV). This virus prepara-
tion is particularly suitable to compare the capacity of Klrk1/
NK cells to resist the challenge by lethal doses of infectious virus.
We observed higher resistance to the viral challenge (2 3 105
plaque-forming units (PFUs) of SGV given intraperitoneally is
equal to LD50 for C57BL/6 mice) of both Klrk1/ and Klrk1+/
mice in comparison to the control mice, regardless of the
m157-Ly49H interaction in this case. As shown on Figure 6B
(left panel), the resistance to SGV infection was abolished by
the depletion of NK cells. To test whether there is a subtle differ-
ence in resistance to SGV between the Klrk1/ and Klrk1+/
mice, we challenged them with higher dose of the virus (3 3
105 PFUs). In this experiment, we obtained clear separation in
Immunity
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panel). The Klrk1+/ mice were more susceptible than Klrk1/
mice but also more resistant than the most susceptible C57BL/6
control.
Different Maturation Kinetics of Klrk1/ NK Cells
during the MCMV Infection
Inasmuch as NKG2D deficiency alters the kinetics of develop-
ment and decay of mature NK cells as well as the functional
capacities (Figures 2–5, Figures S1–S3), we next sought to char-
acterize surface markers and functional properties of peripheral
Klrk1/ NK cells during the early course of MCMV infection.
Klrk1/ and C57BL/6 mice were infected intravenously with
Dm157 MCMV, and their NK cells were analyzed at day 1.5,
2.5, and 5.5 after the infection. First we looked at the absolute
numbers of NK cells in the spleen, which dramatically decreased
at day 1.5 after infection in both strains of mice (Figure 6C). The
NK cell population started to recover between days 2.5 and 5.5
after infection with comparable kinetics between the infected
mouse strains, following the pattern observed previously (Rob-
bins et al., 2004). We then analyzed the expression of various
NK cell markers at the indicated time points after the infection.
The percentages of Ly49H+ NK cells did not change during the
infectionwithDm157MCMVandwere very similar in bothmouse
strains (Figure 6D). Also, we did not notice any significant differ-
Figure 6. Enhanced Resistance of Klrk1/
Mice to MCMV Infection
(A) Groups of Klrk1/, Klrk1+/, and C57BL/6
mice were treated with PBS, aNK1.1 (PK136), or
aNKG2D (C7) prior to intravenous infection with
5 3 105 PFU Dm157 MCMV. Virus titers deter-
mined in the spleen and liver 4 days after the infec-
tion are shown. Each symbol represents an
individual mouse. Median values are indicated as
horizontal lines. The results shown here are repre-
sentative of six independent experiments.
(B) Survival of Klrk1/, Klrk1+/, and C57BL/6
mice upon the infection with either 2 or 3 3 105
PFU of SGV is shown. Control mice treated with
mock-infected salivary gland homogenate (SGH,
dashed line) as well as infected and NK cell
depleted mice are shown (dotted line). Numbers
of mice per group are indicated. Data are repre-
sentative of three independent experiments.
(CandD)KineticsofNKcells in thespleenofKlrk1/
and C57BL/6 mice is shown (C). Percentages of
Ly49H+ or Ly49A+ NK cell populations in the spleen
of theDm157MCMV-infectedmicearedepicted for
each indicated time point (D). Results (C and D) are
expressed as mean ± SD of at least five mice per
group. The results shown here (C and D) are repre-
sentative of two independent experiments.
ence of other activation markers, such
as Ly49D, Ncr1, and CD16, between
the strains, neither in the cell numbers
or the expression amounts (data not
shown). However, in the case of Ly49A,
we noticed that the observed difference
in size of Ly49A+ NK cell populations
between the strains remained during the infection (Figure 6D).
The analysis of CD11b and CD43 expression revealed different
patterns in the maturation dynamics of NK cells between the
strains (Figure 7A). At day 1.5 after infection, we found adecrease
in the percentage of mature NK cell population (CD11bhiCD43hi)
in wild-type (WT) and Klrk1/ mice. This effect was even more
profound at day 2.5 after infection, particularly in the control
mice. However, at day 5.5 after infection, we observed an
increase of CD11bhiCD43hi NK cells in Klrk1/ mice in compar-
ison to the C57BL/6 mice. We also analyzed NK cell subpopula-
tions from spleen regarding the CD27 and CD11b expression
(Figure 7B), markers for the maturity of peripheral NK cells
(Hayakawa and Smyth, 2006). These data were consistent with
the CD11b and CD43 staining. In the first phase of the infection
(until day 2.5), we saw a dramatic decrease of immature
R1 (CD27hiCD11blo) population, as well as the most mature R3
(CD27loCD11bhi) population, but an increase of mature R2
(CD27hiCD11bhi) population with slightly different dynamics
between the strains. The decrease of R3 population was again
faster in Klrk1/ mice. In the NK cell ‘‘recovery phase’’ (upon
day 2.5 after infection), we also observed a faster increase of
the R3 population in Klrk1/ mice (Figure 7B, right panel).
Together, these data show faster maturation and/or migration
dynamics of NK cells in MCMV-infected Klrk1/ mice in
comparison to the control mice.Immunity 31, 270–282, August 21, 2009 ª2009 Elsevier Inc. 277
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Mice Produce IFN-g
Next we addressed the capability of Klrk1/ NK cells to exert
their effector functions during the infection. In the first series of
experiments, we tested whether there are differences in the
percentage of IFN-g-producing NK cells in the spleen between
the infected Klrk1/ and C57BL/6 mice. At the above-indicated
time points, NK cells were briefly treated with rIL-2 and then
tested for IFN-g production by flow cytometry. As is depicted
in Figure 7C, we observed a similar pattern in the percentage
of IFN-g-producing NK cells in both strains of mice, with the
maximum at 1.5 days after infection. However, a larger fraction
of NK cells from Klrk1/ mice produced IFN-g at all tested
time points during the infection as compared to the control.
Consistent with the data described above, we did not observe
any difference in the quantity of this production per cell.
Figure 7. The Maturation Kinetics and Functional
Properties of Klrk1/ NK Cells during the MCMV
Infection
(A and B) Analyses of (A) CD11b and CD43 and (B) CD27 and
CD11b expression on the spleen NK cells at indicated days
after infection with Dm157 MCMV. Representative dot plots
of two independent experiments (3–4 mice per group in
each) are depicted. Results are expressed as mean ± SD.
(C) Analysis of IFN-g-producing NK cells isolated from
Klrk1/ and C57BL6 mice at indicated time points after the
infection is shown. Freshly isolated spleen cells were incu-
bated for 7 hr in the presence of rIL-2 (500 U/ml) and tested
for IFN-g production by intracellular staining. Bars represent
mean percentages ± SDof individual data. The analysis shown
here is representative of three independent experiments (3–4
mice per group in each).
(D) Results of NK cell killing of either uninfected or Dm157
MCMV-infected IC-21 cell targets are shown. The target cells
were infected with 1 PFU/cell and incubated 14 hr before the
staining. Triplicates of samples for each E:T ratio were
analyzed by flow cytometry. Values represent mean percent-
ages ± SD. The results shown here are representative of three
independent experiments.
Because the production of cytokines in NK cells
is differently regulated than cytotoxicity, we also
compared the capacity of Klrk1/ NK cells to kill
MCMV-infected targets to the controls. Either unin-
fected or infected macrophage cell line IC-21 with
wild-type (data not shown) or Dm157 MCMV (Fig-
ure 7D) was used as a target for NK cells. Klrk1/
NK cells were less efficient in killing uninfected
IC-21 targets in comparison to the control,
because of high expression of NKG2D ligands
(data not shown), but they were equally inefficient
as controls in killing infected IC-21 targets either
with WT (data not shown) or with Dm157 MCMV
(Figure 7D).
DISCUSSION
Here we provide evidence for a dual role of NKG2D
in the physiology of NK cells: a regulatory role impli-
cated in development, homeostasis, and survival,
and another important for effector functions. In the absence of
NKG2D, we observed faster division of NK cells, a perturbation
in size of NK cell subpopulations, and augmented NK cell sensi-
tivity to apoptosis. As expected, Klrk1/ NK cells were consid-
erably less responsive to tumor cell targets expressing NKG2D
ligands. However, Klrk1/ NK cells were more responsive to
stimulation through other NK cell activation receptors, and
Klrk1/ mice were more resistant to MCMV infection.
In another recently reported NKG2D-deficient mouse (Guerra
et al., 2008), the authors did not observe major changes in the
developmental subpopulations, and they did not study NK cell
proliferation and apoptosis. It is difficult to reconcile the differ-
ences between the two studies. We both used embryonic stem
cells derived from C57BL/6 mice, and in fact, we both used the
same ES line, so strain differences seem unlikely to have caused
any differences in our findings. Apart from different experimental278 Immunity 31, 270–282, August 21, 2009 ª2009 Elsevier Inc.
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studywas focusedmore on the importance of NKG2Ddeficiency
in the immunosurveillance of tumors. Another possibility is that
the differences are due to different targeting strategies, but this
seems unlikely because most differences in targeting strategies
are due to residual selectable markers, such as neo, that could
affect neighboring genes. However, both groups deleted this
segment from their mutant mice. Thus, only direct comparisons
of both targeted mice with respect to development of NK cells
could settle the question of whether or not these strains really
differ.
Proliferation was enhanced within the immature and mature
NK cell populations of the Klrk1/mice. These changes include
enhanced proliferation in stage II accompanied by a slight accu-
mulation of these cells in the bonemarrow, aswell as the appear-
ance of a larger fraction of functionally capable NK cells in the
periphery. However, we did not observe accumulation of NK
cells in the periphery, most likely because of the higher sensitivity
of Klrk1/NK cells to apoptosis. Thus, our data indicate a previ-
ously unknown regulatory role of NKG2D, which correlates with
its appearance at the very early stages of NK cell development
(Huntington et al., 2007b).
This regulatory function of NKG2D may operate in close
connection with the IL-15R signaling pathway known to be
essential for the development and survival of NK cells (Di Santo,
2006; Huntington et al., 2007a). A potential role for coupling of
DAP10 with the IL-15R signaling pathway was recently
described (Horng et al., 2007). The authors created a transgenic
mouse model where DAP10 was fused with ubiquitin and, thus,
subjected to degradation with consequent downmodulation
of NKG2D. In this model, Stat5 was not phosphorylated and
IL-15R signaling was largely abolished, causing a severe block
in the development of NK cells. Jak3, as a part of the IL-15R
signaling pathway (Jak3-Stat5), appeared to be an essential
kinase for the phosphorylation of DAP10. In contrast, NK cells
in the classical DAP10-deficient mice develop normally, which
may now be ascribed to a redundancy in the signaling system
as a result of the presence of intact NKG2D-DAP12 signaling
complexes on the cell surface (Gilfillan et al., 2002). It has been
shown that Syk can regulate cell survival and cytotoxicity of
NK cells over PI3K (Jiang et al., 2002; Jiang et al., 2003). Simi-
larly, DAP12 deficiency is also redundant and does not cause
developmental defects of NK cells (Bakker et al., 2000; Toma-
sello et al., 2000). Because both signaling pathways, NKG2D
and IL-15R, can activate PI3K, which is implicated in the control
of proliferation, cytotoxicity, and resistance to apoptosis (Bon-
nema et al., 1994; Horng et al., 2007; Jiang et al., 2000; Jiang
et al., 2003; Zompi et al., 2003), the ‘‘unleashed’’ proliferation
as well as augmented sensitivity to apoptosis of NK cells in our
model may be due to a regulatory function of NKG2D controlling
both pathways, where PI3K plays a central role. Recently, it has
been reported that B cell adaptor for PI3K (BCAP), a cytosolic
adaptor molecule that connects the phosphorylated YxxM motif
on membrane receptors or adaptors with PI3K (Okada et al.,
2000), also operates in NK cells (MacFarlane et al., 2008). Inter-
estingly, BCAP-deficient mice featured somewhat slower prolif-
eration of NK cells, increased NK cell numbers in the spleen,
enhanced effector capabilities, and higher resistance to
apoptosis (MacFarlane et al., 2008). In contrast, in transgenicmodels with sustained NKG2D ligands expression like MICA
(Wiemann et al., 2005) and Rae13 (Oppenheim et al., 2005),
and consequent downregulation of NKG2D on NK cells, the
above-discussed phenomenon was not reported, although this
could be related to persistent NK cell stimulation and cross-tol-
erization of other activation receptors (Coudert et al., 2008).
As expected, we observed that Klrk1/ NK cells have mark-
edly lower cytolytic and IFN-g response to NKG2D-sensitive
tumor targets. This finding is in accordance with the study
done on a recently published NKG2D-deficient mouse (Guerra
et al., 2008). Thus, the results from both of the NKG2D-deficient
mice, as well as the data obtained from other models of NKG2D
deficiency (Oppenheim et al., 2005; Wiemann et al., 2005),
confirm important effector functions of NKG2D in the control of
at least some tumors and infections in vivo.
The enhanced resistance ofKlrk1/mice toMCMV, however,
was surprising considering the inability of mice to mount an
NKG2D-dependent virus control because of the viral downmo-
dulation of NKG2D ligands (Bubic et al., 2004; Jonjic et al.,
2008). We expected less or, at most, equal NK cell-mediated
control of the virus in Klrk1/ mice, particularly in the context
of our recent observation that the mature form of Rae1d is rather
resistant to the downmodulation (Arapovic et al., 2009). The
reason for the enhanced resistance of Klrk1/ mice to MCMV
could be a different quality of NK cell response triggered by other
activation receptors or cytokines as a matter of the NK cell dys-
regulation. Proliferation of NK cells during the early phase of
MCMV infection is promoted by IFN-a and IFN-b (Orange and
Biron, 1996), which induces IL-15 (Nguyen et al., 2002). The
presence of IL-15, either in soluble form or trans-presented by
dendritic cells (Burkett et al., 2004; Lucas et al., 2007), can
enhance NK cells proliferation and maturation, particularly in
the absence of NKG2D as discussed above. Recent studies
report specific and vigorous proliferation of Ly49H+ NK cells
during the early MCMV infection, presumably because of their
increased sensitivity to limited amounts of IL-15. This sensitivity
was not a consequence of IL-15R upregulation, but rather of
Ly49H-DAP12-mediated tuning of NK cells (French et al.,
2006). It may well be that NKG2D regulates signaling of Ly49H
as well as of other activation receptors, mediated through
DAP10 and/or DAP12 adaptors, and thus controls proliferation
and survival of NK cells, as discussed above. There is evidence
for close cooperation of NKG2D and other activation receptors in
terms of costimulation (Ho et al., 2002) as well as of cross-toler-
ization upon sustained engagement of NKG2D (Coudert et al.,
2008). Secretion of cytokines like IL-12 and IL-18 during the early
course of the infection could induce IFN-g production in a larger
fraction of the response-capable Klrk1/ NK cells. Therefore,
we believe that the enhanced resistance of NKG2D-deficient
mice to MCMV infection is mainly a consequence of NK cell dys-




C57BL/6, Klrk1+/, and Klrk1/ mice were maintained under specific path-
ogen-free (SPF) conditions at the LaboratoryMouse Breeding and Engineering
Centre (LAMRI), University of Rijeka School of Medicine. All experiments wereImmunity 31, 270–282, August 21, 2009 ª2009 Elsevier Inc. 279
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NKG2D Regulates NK Cell Development and Survivalapproved by the Ethical Committee of the School of Medicine and conducted
in accordance with the international guidelines for animal care and experi-
mental use. Mice were analyzed at the age of 8–10 weeks, if not differently
indicated.
Generation of NKG2D-Deficient Mice
Bruce 4 ES cells (C57BL/6) and feeder cells were grown under conditions
described previously (Kuhn and Torres, 2002). The ES cells (107) were trans-
fected with 30 mg linearized (Not I) pNKG2D-EGFP1 vector (see Supplemental
Experimental Procedures). After positive (G418) and negative (Gancyclovir)
selection, ES cell clones were picked and screened for homologous recombi-
nants by Southern blotting with the external 50 probe a. The internal probe c
was used to exclude random integrations of the vector. For deletion of the
loxP-flanked neo cassette in vitro, two selected clones were transiently trans-
fectedwith pGK-Cre vector and screened for the deletion by Southern blotting.
DNA from G418-sensitive colonies were digested with Stu I and hybridized
with the external probe b. Two neo-deleted ES cell clones were injected into
CB20 blastocysts, which were subsequently transferred into the uteri of F1
(BALB/c x C57BL/6) foster mothers. From each injected clone we obtained
several chimeras, which were crossed to C57BL/6 mice and given germline
transmission of the mutated Klrk1 allele. Mutants were crossed to C57BL/6
three times during the expansion before being maintained in homozygous
breeding. Some experiments, as indicated, were performed on littermates of
heterozygous breeding.
In Vivo BrdU Labeling and Detection
Klrk1/ and C57BL/6 mice were fed with drinking water containing 0.8 mg/ml
BrdU (Sigma) for 11 days prior to the initial time point (day 0). At days 0, 14, and
21, NK cells were isolated from the spleen and bone marrow and stained for
surface markers. After surface staining, the cells were fixed, permeabilized,
and intracellularly labeled with the FITC BrdU Flow kit (BD) according to the
manufacturer’s instructions.
Apoptosis Assay
Freshly isolated splenocytes were cultured in complete RPMI 1640 supple-
mented with 10% FCS (R10) for 14 hr in the presence or absence of rIL-15
(0.5 or 5 ng/ml) or rIL-2 (1000 U/ml, BD). The cells were then stained by Annexin
V-PE with Annexin V Apoptosis Kit (BD) according to the manufacturer’s
instructions.
MCMV Infection
The tissue-culture-grown Dm157MCMV and the salivary gland isolate of wild-
typeMCMV (SGV) were produced and purified, as described previously (Brune
et al., 2001). The mice were treated with aNK1.1+ (PK136, 300 mg/mouse),
aNKG2D (C7, 300 mg/mouse), or PBS 24 hr before intravenous injection of
5 3 105 PFUs of Dm157 MCMV. Four days after the infection, the mice were
sacrificed and viral titers were determined in various organs with the standard
virus plaque assay (Bubic et al., 2004).
For determining the capacity of Klrk1/ NK cells to resist challenge infec-
tion with more virulent MCMV, the mice were infected with either 2 or 3 3
105 PFUs of SGV intraperitoneally. The control groups of mice were treated
with the same amount of salivary gland homogenate isolated from the
mock-infected mice. The mice were treated with either aNK1.1 or PBS 24 hr
prior to the infection. Survival of the mice was monitored during the period
of 30 days after the infection.
Statistics
Statistical significance was calculated by unpaired two-tailed Student’s t test
with Prism4 software (GraphPad Software). The significant differences
between tested groups are indicated with symbols as follows: p < 0.05 (*),
p < 0.01 (**), and p < 0.001 (***). Statistical analyses of the virus titers were
done with the Mann-Whitney U test.
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